Pharmaxis Cancer Drug Pxs-5505 Profiled in Two Posters At American Society of Hematology Conference

News

12th Dec 22

Release Date: 12/12/2022 9:30am

Further analysis of interim data from 6 patients in phase 2 myelofibrosis study; PXS-5505 continues to exhibit an excellent safety profile with encouraging signs of clinical activity in patients ineligible for a JAK inhibitor.
Pharmaxis to discuss next steps in clinical development of PXS-5505 for myelofibrosis with FDA in Q1 2023.
Potential application for PXS-5505 in myelodysplastic syndrome highlighted by promising data released from pre-clinical studies of bone marrow samples from patients.